CD8A and cancer: Immune checkpoint blockade (ICB) cancer therapy, re-activating CD8+ T cells against tumors, has significantly increased patients’ life expectancy and survival.1,2 ICB initiates CD8+ T cell infiltration and results in necrosis, fibrosis, and shrinkage.